GSK Buys UCB Unit | February 2, 2009 Issue - Vol. 87 Issue 5 | Chemical & Engineering News
Volume 87 Issue 5 | pp. 16-17 | Concentrates
Issue Date: February 2, 2009

GSK Buys UCB Unit

Department: Business

GlaxoSmithKline will pay $680 million in cash for the commercial operations and distribution rights for UCB's marketed product portfolio in certain parts of Africa, the Middle East, Asia-Pacific, and Latin America. The deal gives GSK rights to sell the epilepsy drug Keppra and the allergy drugs Xyzal and Zyrtec, among other drugs. It also ties into GSK's recently launched strategy to strengthen its position in emerging markets, which the company says will represent 40% of growth in pharmaceuticals by 2020, in order to reduce its reliance on blockbuster drugs.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment